I'm having serious problem with this sort of reporting and Reuters should do better.
Focusing on sales data is not helpful for vaccine and it would be better to look at doses / patients treated to measure impact.
Sales without looking at expenses are meaningless. Whatever one believes there is a huge cost to this ramp-up. Everything was expedited, expenses secondary.
The cost structure and the risk / reward discussion is required as this is anything but free market. Almost all contracts were involving governments and unusual terms. Typical expenses for drugs like marketing and trials were only to a small part paid by the company.
The rollout of the primary vaccine is still ongoing. If a booster is found to be desirable then it will require similar production capabilities as the vaccine. The sooner this is know the better and the more cost effective this capacity can be ramped up.
Without sufficient planning we may see a conflict of third world vaccines competing with first world booster for production capacity.